Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC

(2014) Rania Gaber et al.   Diagnostic Pathology

Reply to A. Soultati et al

(2014) David Robert Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

HOPE-Fixation of Lung Tissue Allows Retrospective Proteome and Phosphoproteome Studies

(2014) Olga Shevchuk et al.   JOURNAL OF PROTEOME RESEARCH

Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition

(2013) R. Katayama et al.   CANCER RESEARCH

EGF Receptor Activates MET through MAPK to Enhance Non-Small Cell Lung Carcinoma Invasion and Brain Metastasis

(2013) J. L. Breindel et al.   CANCER RESEARCH

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2013) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2

(2013) M. Acunzo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification

(2012) William D. Travis et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

(2012) David R. Spigel et al.   Clinical Lung Cancer

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

(2012) David C. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer

(2012) Rafal Dziadziuszko et al.   Journal of Thoracic Oncology

Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197

(2011) Sudharshan Eathiraj et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

HOPE-BAL

(2011) Sebastian Marwitz et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

(2011) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis

(2010) Elisa Benedettini et al.   AMERICAN JOURNAL OF PATHOLOGY

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

(2010) D. R. Camidge et al.   CLINICAL CANCER RESEARCH

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

(2010) N. Munshi et al.   MOLECULAR CANCER THERAPEUTICS

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

(2009) J. P. Eder et al.   CLINICAL CANCER RESEARCH

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort

(2009) Michèle Beau-Faller et al.   Journal of Thoracic Oncology

Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status

(2009) Takamitsu Onitsuka et al.   LUNG CANCER

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients

(2008) F. Cappuzzo et al.   ANNALS OF ONCOLOGY

MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

(2008) H. Jin et al.   CANCER RESEARCH

Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer

(2008) Katsuhiro Okuda et al.   CANCER SCIENCE

Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer

(2008) L. Toschi et al.   CLINICAL CANCER RESEARCH

Drug development of MET inhibitors: targeting oncogene addiction and expedience

(2008) Paolo M. Comoglio et al.   NATURE REVIEWS DRUG DISCOVERY